General
Preferred name
LUMEFANTRINE
Synonyms
Lumefantrine D18 ()
Benflumetol D18 ()
benflumetol ()
dl-Benflumelol ()
LUMEFANTRINE, (+)- ()
GNF-Pf-1971 ()
CPG-56695 ()
Benflumelol ()
Lumefantrinum ()
P&D ID
PD009278
CAS
120583-69-9
82186-77-4
Tags
available
drug
Approved by
FDA
First approval
2009
Drug Status
approved
Drug indication
Malaria
Max Phase
Phase 4
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Lumefantrine belongs to the aryl amino alcohols, a chemical class of antimalarial compounds that includes , and .
Lumefantrine is a racemic mixture, with PubChem listing 9 stereoisotopes.
The Malaria tab on this ligand page provides additional curator comments of relevance to the Guide to MALARIA PHARMACOLOGY. (GtoPdb)
Lumefantrine is a racemic mixture, with PubChem listing 9 stereoisotopes.
The Malaria tab on this ligand page provides additional curator comments of relevance to the Guide to MALARIA PHARMACOLOGY. (GtoPdb)
DESCRIPTION
Lumefantrine belongs to the aryl amino alcohol class of antimalarial compounds and has activity against the asexual blood stages of P. falciparum.
Lumefantrine is a racemic mixture, with PubChem listing 9 stereoisotopes.
Lumefantrine is listed in the WHO 20th Essential Medicines List (2017) as an antimalarial for curative treatment in combination with . This is one of the artemisinin-based combination therapies (ACTs) recommended in the WHO Guidelines for the treatment of malaria .
Potential Target/Mechanism Of Action: As the precise mechanism of action of lumefantrine is not yet known, we do not have a molecular target for this compound.
Lumefantrine is a racemic mixture, with PubChem listing 9 stereoisotopes.
Lumefantrine is listed in the WHO 20th Essential Medicines List (2017) as an antimalarial for curative treatment in combination with . This is one of the artemisinin-based combination therapies (ACTs) recommended in the WHO Guidelines for the treatment of malaria .
Potential Target/Mechanism Of Action: As the precise mechanism of action of lumefantrine is not yet known, we do not have a molecular target for this compound.
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
0
Organisms
4
Compound Sets
18
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
Enamine BioReference Compounds
Guide to Pharmacology
MedChem Express Bioactive Compound Library
NCATS Inxight Approved Drugs
NPC Screening Collection
Other bioactive compounds
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
33
Molecular Weight
527.15
Hydrogen Bond Acceptors
2
Hydrogen Bond Donors
1
Rotatable Bonds
10
Ring Count
4
Aromatic Ring Count
3
cLogP
9.15
TPSA
23.47
Fraction CSP3
0.33
Chiral centers
1.0
Largest ring
6.0
QED
0.22
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
Parasite
Antiparasitic
Pathway
Anti-infection
Autophagy
Source data
